Gemcitabine for Ovarian Cancer: 8 Real Stories

8 stories match ovarian cancer and gemcitabine. 7 of them mention paclitaxel.

Cancer Stories

A patient, who was diagnosed with Stage III Ovarian CancerOvarian Cancer

Durable response after multiple treatments for ovarian clear cell cancer

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: HRD-positive; BRCA-negative; ARID1A mutation; PD-L1 CPS 30

She achieved a complete response, completed maintenance immunotherapy in May 2024, and continued anlotinib with normal follow-up imaging and tumor markers.

PubMed Central
OutcomeResponding Well
Jennifer, who was diagnosed with Ovarian CancerOvarian Cancer

Ovarian Cancer: Jennifer's Patient Story

Patient Info: Jennifer Thorn, Female, 40s

Living with ovarian cancer and continuing gemcitabine after about 2 years of treatment.

Dana-Farber
OutcomeLiving With Cancer
A patient, who was diagnosed with Ovarian CancerOvarian Cancer

Metastatic Clear Cell Ovarian Cancer Complicated by Treatment-Related Sarcoidosis

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Metastatic Site: peritoneum

During a treatment holiday, biopsy and laboratory evaluation showed treatment-related sarcoidosis rather than ovarian-cancer spread in the enlarged lymph nodes. After prednisone, the sarcoidosis resolved and imaging showed no progression of the clear cell ovarian cancer; she remained clinically well 4 months later.

PubMed Central
OutcomeStable Disease
A patient, who was diagnosed with Stage IV Ovarian AdenocarcinomaOvarian Cancer

Kidney Complications After Treatment for Stage IV Ovarian Cancer

Patient Info: Anonymized, Female, 60s | Stage IV

Metastatic Site: peritoneum|left lymph node

No further ovarian-cancer progression was observed during the 10 months after kidney biopsy. The nephrotic syndrome reached partial remission after immunosuppressive treatment was stopped and supportive care continued.

PubMed Central
OutcomeStable Disease
A patient, who was diagnosed with Ovarian CancerOvarian Cancer

Stable Brain Metastases During Niraparib Maintenance for Ovarian Cancer

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Biomarkers: CA-125 4019 kU/L; pathogenic germline BRCA1 mutation

Metastatic Site: brain

After 17 months of niraparib, her brain metastases remained stable. She had a performance status of 0 and reported a full, normal quality of life.

PubMed Central
OutcomeStable Disease
AO
Ovarian Cancer

Advanced Ovarian Cancer Presenting With Dermatomyositis

Patient Info: Anonymized, Female, 50s

Biomarkers: CA-125 3169 at diagnosis; later CA-125 rise with progression

After a partial response to second-line chemotherapy, nodal disease progressed again 5 months later and liposomal doxorubicin was planned.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage III Ovarian CancerOvarian Cancer

Recurrent Stage III Ovarian Cancer Complicated by Severe Kidney Injury

Patient Info: Anonymized, female, 70+ | Stage III

After further intra-abdominal cancer progression and severe kidney injury, she developed seizures, encephalopathy, and limb ischemia and died 1 week after hospitalization in May 2011.

PubMed Central
OutcomeIn Memory